Thyrocare Technologies IPO to open 27 April
Thyrocare Technologies hopes to raise as much as Rs480 crore and has priced the offer in a band of Rs420-446 per share
Mumbai: Diagnostics firm Thyrocare Technologies Ltd will launch a three-day initial public offering (IPO) on 27 April to raise as much as Rs.480 crore, the company said on Wednesday. The firm has priced the offer in a band of Rs.420-446 per share.
The entire public issue is an offer for sale (OFS) by existing private equity investors and the firm’s promoters.
CX Partners, through its subsidiary company Agalia Pvt. Ltd, has offered to sell about 90% of its holding. The Mauritius-based entity, which holds a stake of about 21%, is the second largest shareholder in the company.
Other private equity investors in the company—Norwest Venture Partners and Samara Capital—are not selling their stakes. Norwest and Samara hold 9.43% and 2%, respectively, in Thyrocare Technologies.
The Navi Mumbai-based operator of pathology laboratories filed its draft prospectus with the Securities and Exchange Board of India (Sebi) on 31 December 2015. It received approval on 24 February.
JM Financial Institutional Securities Ltd, Edelweiss Financial Services Ltd, and ICICI Securities Ltd are bankers to the public issue.
Thyrocare is a pan-India diagnostic chain, which conducts an array of medical diagnostic tests that center on early detection and management of health disorders.
The firm reported a profit of Rs.48.4 crore on revenue of Rs.187 crore for the financial year 2014-15, against a profit of Rs.46.1 crore on revenue of Rs.156.5 crore in the previous financial year.
Thyrocare was looking to list its shares last year, but the issue hit a roadblock after the company was found to be non-compliant with the Companies Act. The firm’s management requested clarification from Sebi in connection to the shares issued to about 51 people about 10 years ago, Mint reported on 26 May last year.
The Companies Act, 1956, did not allow an unlisted company to allot securities to more than 49 investors in a financial year. The clause was relaxed in the Companies Act, 2013, wherein the cap was increased to 200 investors.
Thyrocare’s public issue is the eighth IPO this calendar year. It is being launched at a time when secondary markets have risen 4.75% in the past six sessions. The BSE’s 30-share benchmark Sensex index has advanced more than 12% since mid-February, recovering half of the 23.55% fall from its all-time high of 30,024.74 in March 2015.
Seven firms have tapped primary markets to raise close to Rs.3,200 crore since 1 January, according to Prime Database, which tracks share sales. Last year, 21 firms raised almost Rs.13,600 crore through the IPO route, data showed.
Editor's Picks »
- Future Retail’s Q2 result shows improvement in same-store sales
- Private insurance firms grow at the expense of LIC stuck with a sick bank
- Page Industries’s lofty valuations get a reality check in Q2
- Q2 results: Grasim’s Vodafone Idea stake is proving costly
- How Vodafone Idea’s $3.5 bn fundraising will impact telecom in India